Core Viewpoint - RunDa Medical's stock has shown mixed performance in recent trading sessions, with a slight increase in price but a significant decline in revenue and profit year-over-year [1][2]. Financial Performance - As of September 30, 2025, RunDa Medical reported a revenue of 5.268 billion yuan, representing a year-over-year decrease of 14.70% [2]. - The company experienced a net profit loss of 163 million yuan, a substantial decline of 422.64% compared to the previous year [2]. Stock Performance - On November 25, 2025, RunDa Medical's stock price increased by 2.11%, reaching 16.45 yuan per share, with a total market capitalization of 9.93 billion yuan [1]. - Year-to-date, the stock has risen by 3.46%, with a 3.01% increase over the last five trading days and a 6.61% increase over the last 20 days, while it has decreased by 12.96% over the last 60 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased to 64,800, a reduction of 1.05% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.06% to 9,317 shares [2]. Dividend Information - RunDa Medical has distributed a total of 373 million yuan in dividends since its A-share listing, with 165 million yuan distributed over the past three years [3]. Institutional Holdings - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 4.4119 million shares, a decrease of 48,700 shares from the previous period [3]. - Hong Kong Central Clearing Limited is a new entrant among the top ten shareholders, holding 4.1516 million shares [3].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] - The revenue composition of Titan Technology is as follows: research reagents 42.70%, research instruments and consumables 28.42%, specialty chemicals 26.48%, laboratory construction and research information technology 2.37%, and others 0.02% [1] Financial Performance - As of September 30, Titan Technology reported a total revenue of 1.848 billion yuan for the period from January to September 2025, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, reflecting a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - On November 20, Titan Technology's stock price decreased by 2.01%, trading at 22.92 yuan per share, with a total market capitalization of 3.769 billion yuan [1] - The stock has seen a year-to-date increase of 26.14%, but has declined by 7.99% over the last five trading days, 8.14% over the last 20 days, and 18.26% over the last 60 days [1] - As of the latest data, the number of shareholders is 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Market Activity - The net outflow of main funds was 4.5418 million yuan, with large orders buying 4.3981 million yuan (16.17% of total) and selling 8.9399 million yuan (32.87% of total) [1] - Titan Technology is categorized under the basic chemicals industry, specifically in the chemical products sector, and is associated with concepts such as buybacks, margin financing, pension concepts, scientific instruments, and electronic chemicals [1]

Core Viewpoint - Dian Diagnostics has shown a significant stock price increase of 48.75% year-to-date, despite a recent decline in revenue and net profit [1][2]. Group 1: Stock Performance - On November 18, Dian Diagnostics' stock rose by 2.23%, reaching 16.52 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 103.25 billion CNY [1]. - The stock has experienced a slight increase of 0.06% over the last five trading days, a 7.97% increase over the last 20 days, and a minor decline of 0.12% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 17 [1]. Group 2: Financial Performance - For the period from January to September 2025, Dian Diagnostics reported a revenue of 75.66 billion CNY, reflecting a year-on-year decrease of 18.28%, while the net profit attributable to shareholders was 56.70 million CNY, down 56.67% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 10.99 billion CNY in dividends, with 7.12 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period, with an average of 10,974 shares held per shareholder, an increase of 5.76% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.56 million shares, a decrease of 4.23 million shares from the previous period [3].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, representing a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of November 12, Titan Technology's stock price decreased by 2.15%, trading at 24.13 yuan per share, with a total market capitalization of 3.968 billion yuan [1] - Year-to-date, the stock price has increased by 32.80%, with a slight increase of 0.54% over the last five trading days, but a decline of 0.33% over the last 20 days and 13.33% over the last 60 days [1] - The number of shareholders as of September 30 was 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segmentation - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1] - Titan Technology is classified under the Shenwan industry as basic chemicals - chemical products - other chemical products, and is associated with concepts such as share buybacks, margin financing, electronic chemicals, pension concepts, and scientific instruments [1]

Core Points - Aladdin's stock price increased by 2.07% on November 10, reaching 13.31 CNY per share, with a total market capitalization of 4.427 billion CNY [1] - The company reported a year-to-date stock price increase of 17.44%, with a recent 5-day increase of 3.26% and a 60-day decrease of 11.27% [1] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [1] Financial Performance - For the period from January to September 2025, Aladdin achieved operating revenue of 444 million CNY, representing a year-on-year growth of 17.59% [2] - The net profit attributable to the parent company was 57.76 million CNY, showing a year-on-year decrease of 20.41% [2] Shareholder Information - As of September 30, 2025, the number of Aladdin's shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] - Since its A-share listing, Aladdin has distributed a total of 241 million CNY in dividends, with 150 million CNY distributed in the last three years [3] - Notably, some institutional investors exited the top ten circulating shareholders list as of September 30, 2025 [3]

Core Viewpoint - The launch of the first international academic journal in the field of high-end scientific instruments in China, titled "Advanced Scientific Instruments" (ASI), aims to address the publication challenges in this sector and establish a world-class platform for academic exchange [2][4]. Group 1: Journal Overview - The journal is hosted by China Science Publishing & Media Ltd. and aims to break the "research without platform" dilemma in high-end scientific instruments [2]. - ASI serves as a cross-disciplinary international exchange platform for research results in the fields of instruments, instrumentation, and measurement [4]. Group 2: Journal Sections - Section A focuses on the development of scientific instruments, covering innovative designs, methods, and theoretical aspects [5][6]. - Section B emphasizes new devices and technologies in photonics, lasers, and radar, including various types of spectroscopy and optical metrology [7][8]. - Section C highlights advancements in imaging and microscopy, including micro-nano metrology and real-time image analysis [9][10]. - Section D discusses advanced theories and applications in microelectronics, optoelectronics, and chip-based processes [11][12]. - Section E covers automation in smart instruments, quantum sensing, and various measurement techniques [13][14]. - Section F focuses on new data analysis tools and methods, including machine learning and signal processing [15][16]. Group 3: Industry Context - Currently, there are several related journals in China's scientific instrument industry, such as "Journal of Analytical Chemistry" and "Journal of Instrumentation" [17]. - The inclusion of scientific instruments in national strategic priorities may lead to the emergence of more related journals in the future, potentially influencing procurement decisions for end-users [17].

Core Viewpoint - The stock price of Leibotech has shown a significant increase of 31.52% year-to-date, indicating positive market sentiment towards the company [2]. Group 1: Stock Performance - On November 4, Leibotech's stock rose by 2.01%, reaching a price of 37.57 CNY per share, with a trading volume of 13.31 million CNY and a turnover rate of 0.53% [1]. - The stock has experienced a 2.68% increase over the last five trading days, a 3.93% increase over the last 20 days, and a 2.06% increase over the last 60 days [2]. Group 2: Company Overview - Leibotech, established on January 8, 2002, and listed on September 2, 2020, is located in the Tianzhu Airport Industrial Zone, Shunyi District, Beijing [2]. - The company's main business includes the research, production, and sales of experimental analysis instruments, with revenue composition as follows: 78.82% from experimental analysis instruments, 12.57% from consumables and services, 7.88% from clean and environmentally friendly laboratory solutions, and 0.74% from other sources [2]. Group 3: Financial Performance - For the period from January to September 2025, Leibotech reported a revenue of 285 million CNY, a year-on-year decrease of 8.43%, and a net profit attributable to shareholders of 32.55 million CNY, down 7.26% year-on-year [2]. - As of September 30, 2025, the number of shareholders decreased by 12.49% to 3,181, while the average circulating shares per person increased by 14.27% to 21,204 shares [2]. Group 4: Dividends and Shareholding - Since its A-share listing, Leibotech has distributed a total of 158 million CNY in dividends, with 115 million CNY distributed over the past three years [3]. - As of September 30, 2025, the eighth largest circulating shareholder is Dazheng Rui Xiang Mixed A (008269), holding 568,100 shares, which is a decrease of 114,200 shares compared to the previous period [3].

Core Viewpoint - The stock of 聚光科技 (Juguang Technology) has shown fluctuations in recent trading sessions, with a year-to-date increase of 12.22% but a decline in the last five, twenty, and sixty days [1][2]. Group 1: Stock Performance - As of November 4, the stock price of 聚光科技 reached 16.81 CNY per share, with a trading volume of 32.22 million CNY and a turnover rate of 0.43%, resulting in a total market capitalization of 7.543 billion CNY [1]. - The stock has experienced a net inflow of main funds amounting to 2.4474 million CNY, with significant buying and selling activities recorded [1]. - Year-to-date, the stock has seen a 12.22% increase, but it has declined by 5.56% over the last five trading days, 5.19% over the last twenty days, and 12.81% over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, 聚光科技 reported a revenue of 2.05 billion CNY, reflecting a year-on-year decrease of 11.10%, and a net profit attributable to shareholders of -62.34 million CNY, a significant decline of 152.98% [2]. - The company has distributed a total of 630 million CNY in dividends since its A-share listing, with 112 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for 聚光科技 increased to 23,000, a rise of 13.30%, while the average circulating shares per person decreased by 11.74% to 19,483 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 13.82 million shares, a decrease of 5.19 million shares from the previous period, while Ruiyuan Growth Value Mixed A increased its holdings by 2.42 million shares to 10.86 million shares [3].

Core Insights - Dingyang Technology, established in June 2007 and listed on the Shanghai Stock Exchange in December 2021, is a leading domestic manufacturer of general electronic measurement instruments, benefiting from accelerated domestic substitution [1] Financial Performance - For Q3 2025, Dingyang Technology reported revenue of 431 million yuan, ranking 26th in the industry, with the industry leader, Chuan Instrument, at 4.89 billion yuan [2] - The net profit for the same period was 111 million yuan, ranking 13th in the industry, with the top performer, Chuan Instrument, at 469 million yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 7.57%, lower than the industry average of 27.43%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 61.13%, above the industry average of 43.50%, reflecting robust profitability [3] Executive Compensation - The chairman, Qin Ke, received a salary of 749,000 yuan in 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 39.69% to 7,271, while the average number of shares held per shareholder decreased by 28.41% to 21,900 shares [5] - Notable changes in the top ten shareholders included Hong Kong Central Clearing Limited increasing its holdings by 454,100 shares [5] Business Highlights - Dingyang Technology's Q3 2025 revenue reached a historical peak of 153 million yuan, with a net profit of 34 million yuan [5] - The company saw a 71.92% year-on-year increase in revenue from high-end products, with high-resolution oscilloscopes and microwave RF products showing significant growth [6] - The company plans to release new high-end products, including the SDS8000A oscilloscope in 2025 [5]

Core Viewpoint -坤恒顺维 is a leading enterprise in the high-end radio testing and simulation instrument sector in China, with strong competitive advantages due to high technical barriers in its products [1] Group 1: Business Overview -坤恒顺维 was established on July 14, 2010, and went public on February 15, 2022, on the Shanghai Stock Exchange, with its registered and office location in Sichuan Province [1] - The company focuses on the R&D, production, and sales of high-end radio testing and simulation instruments, targeting mobile communications, wireless networking, and radar fields [1] - The company operates within the communication equipment sector, with relevant concept segments including small-cap, scientific instruments, satellite navigation, nuclear fusion, superconductivity, and nuclear power [1] Group 2: Financial Performance - For Q3 2025,坤恒顺维 reported revenue of 157 million, ranking 12th in the industry, significantly lower than the industry leader, Oriental Communication, at 1.627 billion, and the second-ranked Longwei Shares at 903 million [2] - The net profit for the same period was 26.19 million, ranking 5th in the industry, below Oriental Communication's 359 million and Yinhantong's 105 million, but above the industry average of 34.39 million [2] Group 3: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 15.93%, an increase from 13.33% year-on-year, which is lower than the industry average of 26.75%, indicating good solvency [3] - The gross profit margin for the same period was 61.37%, down from 64.56% year-on-year, but still above the industry average of 36.75%, reflecting strong profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 31.60% to 3,240, with an average holding of 37,600 circulating A-shares, up by 8.26% [5] - In the first half of 2025, the company achieved revenue of 102 million, a year-on-year increase of 26.69%, while net profit decreased by 8.49% to 12.81 million [5] - The company is expected to see net profits of 41.6 million (+12.3%), 62.86 million (+51.1%), and 94.43 million (+50.2%) for the years 2025 to 2027, respectively [5]